Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 6/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.39 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | LAP3 | P28838 | 4/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21978408 | 0.83 | — | — | |
| SCHEMBL9100153 | 0.82 | SLC7A5 (0.58) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL995721 | 0.82 | SLC7A5 (0.58) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL8629207 | 0.79 | HTT (0.30) | — | |
| SCHEMBL1681788 | 0.78 | GRIN2D (0.32) | — | |
| SCHEMBL4576494 | 0.78 | DPP4 (0.33) | — | |
| SCHEMBL9481259 | 0.77 | PTGS1 (0.41) | — | |
| SCHEMBL998946 | 0.76 | SLC7A5 (0.52) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL1585736 | 0.76 | SLC7A5 (0.52) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL7676359 | 0.76 | SLC7A5 (0.52) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104507899-A | Phenol derivative, preparation method and medical application thereof | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2015-04-08 | — | — | CN | disclosed |
| CN-101137665-A | Desoxo-nonadepsipeptides | AICURIS GMBH & CO KG (DE) | 2008-03-05 | — | — | CN | disclosed |
| EP-1087935-B1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INT LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20030203975-A1 | Anti-cancer agents | BTG INTERNATIONAL LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1087935-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065866-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
| US-5689039-A | HERBICIDE RESISTANCE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0577775-A4 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES. | RHONE POULENC RORER INT (US) | 1995-01-11 | — | — | EP | disclosed |
| EP-0577775-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1994-01-12 | — | — | EP | disclosed |
| WO-1992017196-A1 | ANTI-THROMBOTIC PEPTIDES AND PSEUDOPEPTIDES | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203975-A1 | Anti-cancer agents | TOP2B, TOP2A, TOP1 | SLC7A5 757/4885ANPEP 364/4885RNPEP 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.